Drugabilis is a French CRO specializing in early pharmaceutical development. For over 20 years, we have supported biotech and pharma companies in assessing drug developability, designing tailored preclinical formulations for efficacy, PK and toxicology studies, and optimizing API solid forms (salts, polymorphs, co-crystals). Our expertise also helps anticipate formulation challenges and guide early clinical development strategies for small molecules and peptides.